Comparison of the effects of sitagliptin and mitiglinide/voglibose fixed-dose combination tablets on glucose metabolism in patients with uncontrolled type-2 diabetes mellitus

INTERVENTION: a group in which the dose of sitagliptin is to be increased from 50 mg to 100 mg (S group) a group in which sitagliptin (50 mg) is to be switched to mitiglinide/voglibose fixed‐dose combination tablets (MV group) CONDITION: type‐2 diabetes mellitus PRIMARY OUTCOME: SD value SECONDARY OUTCOME: MAGE, mean glucose level over 24 hours, frequency of glucose levels &#8805; 180 mg/dL and < 70 mg/dL, Endo‐PAT measurement, incidence of adverse reactions. INCLUSION CRITERIA: 1) Patients treated with 50 mg of sitagliptin for at least 12 weeks, but who do not achieve the therapeutic goal: HbA1c < 6.5% (HbA1c upper limit: < 8.0%, fluctuation range: within 0.5%). 2) Outpatients aged 20 or older. 3) Patients who have agreed in writing to participate in the study.